Literature DB >> 10203365

Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease.

M Abbate1, C Zoja, D Rottoli, D Corna, N Perico, T Bertani, G Remuzzi.   

Abstract

In proteinuric glomerulopathies, the excess traffic of proteins into the renal tubule is a candidate trigger of interstitial inflammatory and immune events leading to progressive injury, and a key target for the renoprotective action of antiproteinuric drugs. Among proteins trafficked to the proximal tubule, the third component of complement (C3) can be activated locally and contribute to inflammation at sites of protein reabsorption. Experiments were performed in rats with renal mass reduction (RMR, 5/6 nephrectomy) with the following aims: (1) to study Ig (IgG) and complement deposition in proximal tubules, and interstitial macrophage infiltration and MHC class II expression at intervals after surgery by double immunofluorescence analysis; (2) to assess whether lisinopril (angiotensin-converting enzyme inhibitor [ACEi], 25 mg/L in the drinking water, from either day 1 or day 7) limited IgG and C3 accumulation and interstitial inflammation at day 30. In 7-d remnant kidneys, intracellular staining for both IgG and C3 was detectable in proximal tubules in focal areas; C3 was restricted to IgG-positive tubular cells, and there were no interstitial ED-1 macrophage and MHC II-positive cellular infiltrates. In 14-d and 30-d remnant kidneys, proximal tubular IgG and C3 staining was associated with the appearance of interstitial infiltrates that preferentially localized to areas of tubules positive for both proteins. RMR rats given ACEi had no or limited increases in levels of urinary protein excretion, tubular IgG, and C3 reactivity, and interstitial cellular infiltrates in kidneys at 30 d, even when ACEi was started from day 7 after surgery. These findings document that (1) in RMR, IgG and C3 accumulation in proximal tubular cells is followed by leukocyte infiltration and MHC II overexpression in the adjacent interstitium; (2) ACEi while preventing proteinuria limits both tubular accumulation of IgG and C3 and interstitial inflammation. The data suggest that ACE inhibition can be renoprotective by limiting the early abnormal protein traffic in proximal tubule and consequent deleterious effects of excess protein reabsorption, including the accumulation and local activation of complement as well as the induction of chemokines and endothelin genes known to promote interstitial inflammation and fibrosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203365     DOI: 10.1681/ASN.V104804

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  19 in total

Review 1.  Role of ACE inhibitors in patients with diabetes mellitus.

Authors:  D J Cordonnier; P Zaoui; S Halimi
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis.

Authors:  Mauro Abbate; Carla Zoja; Marina Morigi; Daniela Rottoli; Stefania Angioletti; Susanna Tomasoni; Cristina Zanchi; Lorena Longaretti; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 3.  Complement activation in progressive renal disease.

Authors:  Amy Fearn; Neil Stephen Sheerin
Journal:  World J Nephrol       Date:  2015-02-06

Review 4.  Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.

Authors:  Raimund Pichler; Maryam Afkarian; Brad P Dieter; Katherine R Tuttle
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-24

5.  The effect of progressive glomerular disease on megalin-mediated endocytosis in the kidney.

Authors:  Lotte Vinge; George E Lees; Rikke Nielsen; Clifford E Kashtan; Anne Bahr; Erik I Christensen
Journal:  Nephrol Dial Transplant       Date:  2010-03-02       Impact factor: 5.992

Review 6.  Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Authors:  Michael S Kostapanos; Christos V Rizos; Moses S Elisaf
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

Review 7.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

8.  Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury.

Authors:  Mauro Abbate; Carla Zoja; Daniela Corna; Daniela Rottoli; Cristina Zanchi; Nadia Azzollini; Susanna Tomasoni; Silvia Berlingeri; Marina Noris; Marina Morigi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 10.121

9.  Diabetic albuminuria is due to a small fraction of nephrons distinguished by albumin-stained tubules and glomerular adhesions.

Authors:  Patricia M Kralik; Yunshi Long; Ye Song; Lu Yang; Haiyang Wei; Susan Coventry; Shirong Zheng; Paul N Epstein
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

10.  Beneficial effect of triple treatment plus immunoglobulin in experimental nephrotic syndrome.

Authors:  Sema Akman; Salih Kalay; Bahar Akkaya; Mustafa Koyun; Halide Akbaş; Yunus Emre Baysal; Ayfer Gur Guven
Journal:  Pediatr Nephrol       Date:  2009-02-18       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.